# Urinary follicle stimulating hormone (FSH) usage in in vitro fertilisation (IVF) cycles

Submission date	Recruitment status	[X] Prospectively registered
22/05/2008	No longer recruiting	☐ Protocol
Registration date	Overall study status	Statistical analysis plan
23/06/2008	Completed	Results
Last Edited	Condition category	Individual participant data
14/02/2019	Pregnancy and Childbirth	<ul><li>Record updated in last year</li></ul>

#### Plain English summary of protocol

Not provided at time of registration

#### Contact information

#### Type(s)

Scientific

#### Contact name

Dr Ulun Ulug

#### Contact details

Alman Hastanesi Sýraselviler Cad No 117 Istanbul Türkiye 80200

\_

ulunulug@superonline.com

#### Additional identifiers

**EudraCT/CTIS** number

**IRAS** number

ClinicalTrials.gov number

NCT00677573

Secondary identifying numbers

N/A

## Study information

#### Scientific Title

Comparison of efficiency of recombinant follicle stimulating hormone (rec-FSH) and highly purified urinary follicle stimulating hormone (FSH) among women undergoing assisted reproductive treatment (ART)

#### **Study objectives**

One of the most accepted patient friendly ovulation induction method for patients undergoing IVF seems to be protocols with gonadotropin-releasing hormone (GnRH) antagonist. Conceivably benefits of luteinising hormone (LH) activity and low cost may favor urinary gonadotropins.

#### Ethics approval required

Old ethics approval format

#### Ethics approval(s)

Ethics approval received from the Ethics Committee of the German Hospital in Istanbul on the 2nd May 2008 (ref: 17).

#### Study design

Prospective randomised controlled trial

#### Primary study design

Interventional

#### Secondary study design

Randomised controlled trial

#### Study setting(s)

Hospital

#### Study type(s)

Treatment

#### Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

#### Health condition(s) or problem(s) studied

Primary infertility

#### **Interventions**

Group A: starts with recombinant FSH (r-FSH) Group B: starts with only urinary FSH (u-FSH)

In both groups GnRH antagonist will be initiated when leading follicle is 13 mm or on day 6 of stimulation.

#### Interventions:

Serum assays of baseline FSH, LH, oestrogen (E2), progesterone, testesterone on day 2 of cycle

and serum assays of LH, E2, testosterone and progesterone on human chorionic gonadotropin (HCG) day and ovum pick-up (OPU) day.

#### Intervention Type

Other

#### **Phase**

**Not Specified** 

#### Primary outcome measure

Number of oocytes retrieved, 12 days following embryo transfer.

#### Secondary outcome measures

- 1. Pregnancy rate
- 2. Implantation rate
- 3. Duration of stimulation
- 4. Gonadotropin consumption

All secondary outcomes measured at 12 days following embryo transfer.

#### Overall study start date

25/06/2008

#### Completion date

30/11/2008

# **Eligibility**

#### Key inclusion criteria

- 1. Women less than 42 years old
- 2. Healthy

#### Participant type(s)

Patient

#### Age group

Adult

#### Sex

Female

#### Target number of participants

200

#### Key exclusion criteria

- 1. Any of the ovary removed surgically
- 2. Surgically retrieved spermatozoa
- 3. FSH level over 13 mIU/ml

#### Date of first enrolment

# Date of final enrolment 30/11/2008

#### Locations

#### **Countries of recruitment** Türkiye

Study participating centre Alman Hastanesi Istanbul

# Sponsor information

#### Organisation

Türkiye 80200

Bahceci Women Health Care Center (Turkey)

#### Sponsor details

Azer Is Merkezi 44-17 Abdi Ipekci Cad Nisantasi Isanbul Türkiye 80200 +90 (9)212 230 0809 mbahceci@superonline.com

#### Sponsor type

Hospital/treatment centre

# Funder(s)

#### Funder type

Hospital/treatment centre

#### **Funder Name**

Bahceci Women Health Care Center (Turkey)

#### Funder Name

German Hospital in Istanbul (Turkey)

### **Results and Publications**

**Publication and dissemination plan**Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

**IPD sharing plan summary**Not provided at time of registration